Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Apricus Biosciences, Inc. (APRI - Snapshot Report) and Takeda Pharmaceuticals recently signed an exclusive licensing agreement to market Apricus’ Vitaros in the UK. The drug is indicated for the treatment of erectile dysfunction.

Per the terms of the deal, Takeda will make an upfront payment (details of which were not revealed) in addition to milestone payments of up to €35 million to NexMed, a wholly owned subsidiary of Apricus. As per IMS Health, the erectile dysfunction market in the UK was about €202 million in 2011.

We note that Vitaros is already approved in Canada. Moreover, the European Medicines Agency accepted the marketing authorization application for Vitaros in mid 2011. The company expects the drug to be approved in the EU in 2013.

Apricus has several agreements for Vitaros. The company has a marketing agreement with Abbott Laboratories (ABT - Analyst Report) in Canada. In Germany, Apricus has a partnership agreement with Novartis AG’s (NVS - Snapshot Report) Sandoz for Vitaros. Apart from these Apricus has agreements with Warner Chilcott plc , Bracco SpA, Neopharm Group, Elis Pharmaceuticals and Global Harvest Pharmaceuticals for the drug in the US, Italy, Israel, Middle-East and Australia/New Zealand, respectively. The company also has a clinical supply agreement with Warner Chilcott UK Limited for Vitaros.

Apricus’ other marketed drugs include Totect (extravasation from intravenous anthracycline chemotherapy), Granisol (nausea and vomiting associated with radiation and chemotherapy), NitroMist (angina pectoris) and Aquoral (management of dry mouth).

Our Recommendation

We currently have a Neutral recommendation on Apricus. The stock carries a Zacks #3 Rank (Hold rating) in the short run.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
BITAUTO HOLD BITA 35.33 +14.82%
ANI PHARMACE ANIP 24.79 +14.66%
E HOUSECHINA EJ 10.99 +9.24%
CANADIAN SOL CSIQ 26.97 +7.15%
INTERNATIONA ICAGY 33.30 +5.38%